<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606866</url>
  </required_header>
  <id_info>
    <org_study_id>12977A</org_study_id>
    <nct_id>NCT00606866</nct_id>
  </id_info>
  <brief_title>MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma</brief_title>
  <acronym>MRI</acronym>
  <official_title>Dynamic-Contrast Enhanced MRI Pharmacodynamic Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine maximum tumor shrinkage, time to progression,&#xD;
      survival, drug concentration, and degree of skin toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether a new experimental MRI technique called &quot;Dynamic Contrast Enhanced MRI&quot; (DCE-MRI) can determine the best dose of sorafenib</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To predict which patients are most likely to experience tumor shrinkage.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib, 200 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib, 400 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo for four weeks</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 200 mg twice daily</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib, 400 mg twice daily</description>
    <arm_group_label>III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic clear cell renal cell cancer;&#xD;
&#xD;
          -  At least one lesion that can be accurately measured in at least one dimension;&#xD;
&#xD;
          -  Patients must not have been treated with prior anti-timor kinase inhibitors or VEGF&#xD;
             pathway inhibitors;&#xD;
&#xD;
          -  Age 18 and older;&#xD;
&#xD;
          -  ECOG performance status 0-2;&#xD;
&#xD;
          -  Blood pressure higher than 140/90 on 2 separate occasions not more than 6 weeks prior&#xD;
             to enrollment and not less than 24 hours apart;&#xD;
&#xD;
          -  Normal organ function: total bilirubin less than upper limit of normal, AST less than&#xD;
             2.5 X upper limit of normal, creatinine less than 2.8 mg/dl;&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             prior to study entry and for the duration of study participation;&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy or radiotherapy within 4 weeks prior to entering the study;&#xD;
&#xD;
          -  Any other investigational agents;&#xD;
&#xD;
          -  Known brain metastases;&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including ongoing or active infection, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements;&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2008</study_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal, metastatic, carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

